Accessnewswire·2025-11-03 14:01Core Insights - CASI Pharmaceuticals, Inc. is developing CID-103, a potential best-in-class anti-CD38 monoclonal antibody for organ transplant rejection and autoimmune diseases [1] - The company announced that data from its Phase 1 open-label study of CID-103 in adult patients with immune thrombocytopenia (ITP) will be presented at the 67th American Society of Hematology Annual Meeting [1] Company Overview - CASI Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on innovative therapies for serious diseases [1] - CID-103 is being investigated for its efficacy in treating patients with immune thrombocytopenia, a condition characterized by low platelet counts [1] Study Details - The Phase 1 study is a dose-escalation and safety study followed by a randomized, open-label, parallel-arm multi-dose study [1] - The study evaluates the efficacy and tolerability of CID-103 in adults with persistent or chronic immune thrombocytopenia [1] - The presentation will take place during the session named 311 at the annual meeting scheduled for December 6-9, 2025, in Orlando, Florida [1]